Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jennifer Kayden Lee Insider Profile
4 Followers
Jennifer Kayden Lee, EVP, Head of North America at Rhythm Pharmaceuticals, holds 6.85K shares in Rhythm Pharmaceuticals (Ticker: RYTM).
Jennifer Kayden Lee has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Jennifer Kayden Lee's holdings
Insider Roles
EVP, Head of North America
Roles that Jennifer Kayden Lee holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Jennifer Kayden Lee
Jennifer Kayden Lee's Trading History
List of latest transactions for each holding click on a transaction to see Jennifer Kayden Lee's performance on stock
You May Also Like
Jennifer Kayden Lee insider profile FAQ
What is the percentage of profitable transactions made by Jennifer Kayden Lee?
The percentage of profitable transactions made by Jennifer Kayden Lee is ―.
What is the average return per transaction made by Jennifer Kayden Lee?
The average return per transaction made by Jennifer Kayden Lee is ―.
What stocks does Jennifer Kayden Lee hold?
Jennifer Kayden Lee holds: RYTM stocks.
What was Jennifer Kayden Lee’s latest transaction?
Jennifer Kayden Lee latest transaction was an Uninformative Sell of $707.00K.
What was Jennifer Kayden Lee's most profitable transaction?
Jennifer Kayden Lee’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Jennifer Kayden Lee's role in Rhythm Pharmaceuticals?
Jennifer Kayden Lee's role in Rhythm Pharmaceuticals is EVP, Head of North America.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.